FDA Approves Gilead’s Yeztugo® (Lenacapavir) as First Biannual Injectable HIV PrEP
Gilead Sciences, Inc. (Nasdaq: GILD) has announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir) as
Read more
HIV
EC Greenlights ViiV Healthcare and J&J’s HIV-1 Combo for Adolescents
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced today that
Read more
Moderna Starts HIV Vaccine Trial that Uses Breakthrough mRNA Technology
The first doses of an experimental HIV vaccine antigen have been provided in a clinical study at George Washington University
Read more
University of Oxford Starts Phase I Clinical Trial of Novel HIV Vaccine
The University of Oxford has commenced a Phase I clinical trial of a novel HIV vaccine candidate with vaccinations underway
Read more
CABENUVA approved by the FDA as first long-acting HIV regimen
The U.S FDA has given the green light to Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for
Read more
ViiV Healthcare’s two-drug combo non-inferior to 3-drug HIV regimen
ViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read more
Enzolytics and BioClonetics intent to merge sends stock parabolic
Enzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read more